FLNA ▼ -1.4% - Filana Therapeutics, Inc. $FLNA - Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Filana Therapeutics' stock declined 1.4% despite the company announcing that the FDA has lifted a clinical hold on its simufilam program, clearing the way for a Phase 2a study in tuberous sclerosis complex-related epilepsy. The regulatory clearance removes a previous obstacle to development, though investors may have already priced in expectations for this outcome or are adopting a cautious stance ahead of the upcoming trial. 22-SEP-2026 08:01 AM ET